

1 **TITLE**

2 ENDOTHELIAL CELL-DERIVED EXTRACELLULAR VESICLES ELICIT
3 NEUTROPHIL DEPLOYMENT FROM THE SPLEEN FOLLOWING ACUTE
4 MYOCARDIAL INFARCTION

5

6 **One Sentence Summary**

7 Extracellular vesicles mediate neutrophil mobilisation from the spleen following acute
8 myocardial infarction.

9

10 **Authors**

11 Naveed Akbar¹, Adam T. Braithwaite¹, Emma M. Corr², Graeme J. Koelwyn², Coen
12 van Solingen², Clément Cochain³, Antoine-Emmanuel Saliba⁴, Alastair Corbin⁵,
13 Daniela Pezzolla¹, Laurienne Edgar¹, Mala Gunadasa-Rohling⁶, Abhirup Banerjee¹,
14 Daan Paget¹, Charlotte Lee¹, Eleanor Hogg¹, Adam Costin⁷, Raman Dhaliwal⁷, Errin
15 Johnson⁷, Thomas Krausgruber⁸, Joey Riepsaame⁷, Genevieve E. Melling⁹,
16 Mayooran Shanmuganathan^{1, 10, 11}, Oxford Acute Myocardial Infarction Study
17 (OxAMI)^{1, 10, 11}, Christoph Bock^{8,12}, David R. F Carter⁹, Keith M. Channon^{1, 10, 11}, Paul
18 R. Riley⁶, Irina A. Udalova⁵, Kathryn J. Moore², Daniel Anthony¹³, Robin P.
19 Choudhury^{1, 10, 11}

20

21 **Affiliations**

22 ¹Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of
23 Oxford.

24 ²NYU Cardiovascular Research Center, Department of Medicine, Division of
25 Cardiology, School of Medicine, New York University School of Medicine

26 ³Comprehensive Heart Failure Center, University Hospital Wurzburg, Germany

27 ⁴Helmholtz Institute for RNA-based Infection Research (HIRI), Helmholtz-Center for

28 Infection Research (HZI)

29 ⁵Kennedy Institute of Rheumatology, University of Oxford.

30 ⁶Department of Physiology, Anatomy and Genetics, University of Oxford.

31 ⁷Sir William Dunn School of Pathology, University of Oxford.

32 ⁸CeMM Research Center for Molecular Medicine of the Austrian Academy of
33 Sciences, Vienna, Austria.

34 ⁹Department of Biological and Medical Sciences, Oxford Brookes University.

35 ¹⁰The OxAMI Study is detailed in the Supplemental Acknowledgments.

36 ¹¹Acute Vascular Imaging Centre, Radcliffe Department of Medicine, University of
37 Oxford.

38 ¹²Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria.

39 ¹³Department of Pharmacology, University of Oxford.

40

41 **Corresponding Author**

42 Professor Robin Choudhury

43 Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of

44 Oxford.

45 robin.choudhury@cardiov.ox.ac.uk

46 **Abstract**

47 Acute myocardial infarction rapidly increases blood neutrophils (<2 hours). Release
48 of neutrophils from bone marrow, in response to chemokine elevation, has been
49 considered their source, but chemokine levels peak up to 24 hours after injury, and
50 *after* neutrophil elevation. This suggests that additional non chemokine-dependent
51 processes may be involved. Endothelial cell (EC) activation promotes the rapid (<30
52 minutes) release of extracellular vesicles (EVs), which are enriched in vascular cell
53 adhesion molecule-1 (VCAM-1) and miRNA-126, and are thus a potential
54 mechanism for communicating with remote tissues.

55 Here, we show that injury to the myocardium rapidly mobilises neutrophils from the
56 spleen to peripheral blood and induces their transcriptional activation prior to their
57 arrival at injured tissue. Ischemic myocardium leads to the generation and release of
58 EC-derived-EVs bearing VCAM-1. EC-EV delivery to the spleen alters inflammatory
59 gene and chemokine protein expression, and mobilises neutrophils to peripheral
60 blood. Using CRISPR/Cas9 genome editing we generated VCAM-1-deficient EV and
61 showed that its deletion removed the ability of EC-EV to provoke the mobilisation of
62 neutrophils. Furthermore, inhibition of miRNA-126 *in vivo* reduced myocardial
63 infarction size in a mouse model. Our findings show a novel mechanism for the rapid
64 mobilisation of neutrophils to peripheral blood from a splenic reserve, independent of
65 classical chemokine signalling, and establish a proof of concept for functional
66 manipulation of EV-communications through genetic alteration of parent cells.

67

68 **Introduction**

69 Acute myocardial infarction (AMI) is a substantial sterile injury that leads to a rapid
70 increase in peripheral blood neutrophils (1-5). Elevated peripheral blood neutrophil
71 number post-AMI correlates with the extent of myocardial injury, degree of cardiac
72 dysfunction, and mortality (1-3). Defective neutrophil removal enhances susceptibility
73 to cardiac rupture (6) and inhibition of neutrophil recruitment in AMI reduces infarct
74 size (1), but antibody depletion of neutrophils prior to AMI increases infarct size,
75 enhances fibrosis and lowers the number of M2 macrophages in the healing
76 myocardium (1, 7). These findings suggest a complex role for neutrophils in the
77 contexts of myocardial ischaemic injury and repair.

78 The bone marrow is the primary site for granulopoiesis (8, 9) and has been regarded
79 as the principal source of neutrophils that are mobilised to peripheral blood after
80 injury (4, 10). Mature neutrophils are held in large numbers in the haemopoietic
81 cords, separated from the blood by the sinusoidal endothelium (11). In the current
82 paradigm, these cells are retained in the marrow by the interaction of CXCR4 and
83 CXCL12 (stromal cell derived factor (SDF-1 α)) (12) and mobilised in response to
84 soluble factors. Intravascular injection of a range of chemotactic factors, including
85 leukotriene B₄, C5a, interleukin-8 (IL-8) (13), CXCL chemokines (12, 14) and
86 granulocyte-colony stimulating factor (G-CSF) (15, 16) can drive the rapid
87 mobilisation of neutrophils across the sinusoidal endothelium. However, numerous
88 strands of evidence question whether chemokines derived from injured tissues are
89 responsible for very early neutrophil mobilisation *in vivo*. Intra-cardiac mRNA levels
90 for cytokines peak 12 hours after injury (17) and pro-inflammatory proteins are very
91 modestly elevated in coronary sinus following reperfusion therapy in AMI (18, 19).
92 Furthermore, *in vivo* blood chemokine profiles peak 24 hours post-AMI and do not

93 precede the rise in blood neutrophil counts in humans or mice, which occurs within 2
94 hours in mice following injury (1, 20). Moreover, a putative source of chemokine
95 generation in the acutely ischemic myocardium prior to neutrophil infiltration has not
96 been identified.

97 These observations suggest that neutrophils may be mobilised from alternative
98 reserves following injury and by mechanisms that are not dependent on chemokines.
99 One possible source is extramedullary haematopoiesis in the spleen (21) from where
100 neutrophils are mobilised to peripheral blood following bacterial infection (22). By
101 analogy, it is known that monocytes are deployed from a splenic reserve and not
102 from the bone marrow following sterile injury in mice (23), and that this can be driven
103 by extracellular vesicles (EVs) that are derived from the vascular endothelium (24).

104 EVs are membrane-enclosed envelopes (25) that are actively secreted by many cell
105 types (26-28). These vesicles bear bioactive cargo that includes proteins and
106 microRNAs (miRNAs), which are derived from the parent cell. EV can alter the
107 biological function and cellular status of cells locally (29) and remotely following
108 liberation into the blood (30). Endothelial cell (EC) derived-EVs bearing vascular cell
109 adhesion molecule-1 (VCAM-1) are elevated in the blood following AMI (24, 29) and
110 have a role in the mobilisation and transcriptional programming of splenic monocytes
111 in AMI (24).

112 Here, we sought to establish whether EC-EVs contribute to the mobilisation and
113 programming of neutrophils and, if so, through which of their component parts. We
114 hypothesised that EC-EVs released during ischaemia would localise to neutrophils in
115 remote reserves in a process mediated by VCAM-1, which has been shown to bind
116 to neutrophils via surface integrins (31). Furthermore, we reasoned that once

117 localised to neutrophils in reserve pools, EC-EV miRNA cargo could induce
118 functionally relevant transcriptional programmes in those target tissues and cells
119 prior to recruitment to the injured myocardium. An understanding of these
120 mechanisms would immediately suggest possibilities for cell-selective immuno-
121 modulatory interventions that are relevant in AMI and, potentially, other pathologies
122 with an inflammatory component.

123 Accordingly, we investigated changes in the number and composition of EC-EVs in
124 mice and humans in the context of AMI, examined their tissue distribution and effects
125 on cell mobilisation and programming *in vitro* and *in vivo*. We used bioinformatics
126 techniques to identify plausible bioactive candidates and evaluated their functional
127 significance experimentally *in vivo* using antagomir and gene editing approaches.

128 **Results**

129 **Plasma neutrophil number correlates with the extent of AMI**

130 During acute ST-segment-elevation AMI (STEMI) in human patients (median time
131 from onset of symptoms 3 hours) peripheral blood neutrophil number at the time of
132 presentation correlated with the extent of ischaemic injury, as determined by oedema
133 estimation on T2-weighted magnetic resonance imaging (MRI) images obtained
134 within 48 hours of AMI ($R^2 = 0.365$, $P = 0.017$) (**Figure 1A**) and with final infarct size,
135 determined by late gadolinium enhancement (LGE) MRI 6 months post-AMI (R^2
136 $= 0.507$, $P = 0.003$) (**Figure 1B**).

137

138 **AMI mobilises neutrophils from the spleen**

139 This rapid increase in peripheral blood neutrophils would be consistent with
140 mobilisation from an existing reserve. To determine the source of neutrophil
141 mobilisation in the immediate hours post-AMI we performed left anterior descending
142 (LAD) artery ligation in a mouse model of AMI and analysed cell populations from
143 multiple tissue sources, 2 hours after AMI, by flow cytometry (**Figure 1C**). AMI
144 induced a 6.3-fold ($P < 0.01$) increase in peripheral blood neutrophils (Live, $CD45^+$,
145 $CD11b^+$, $Ly6G^+$) and simultaneously lowered splenic-neutrophil number by 0.7-fold
146 ($P < 0.001$) (**Figure 1D**). As described previously, to obtain an indication of the
147 mobilisation between reserves, we calculated a neutrophil mobilisation ratio (24)
148 (peripheral blood neutrophils/ splenic [or bone marrow] neutrophils) and found an
149 increase in splenic neutrophil-mobilisation (8.5-fold) ($P < 0.01$), but no alteration in
150 bone marrow neutrophil number relative to control animals. There was no alteration
151 in $CD62L/L$ -selectin (which is shed during neutrophil activation) in mobilised

152 peripheral blood neutrophils (**Figure 1E**). At this very early time point (2 hours post-
153 AMI), we found no differences in LyC6^{high} monocyte number in the peripheral blood
154 or spleen, indicating that neutrophils mobilise from the spleen prior to splenic-
155 monocyte mobilisation (23) (**Figure 1F**).

156

157 **Plasma EVs correlate with the extent of injury and neutrophil count in AMI**

158 Following AMI EC-EVs are significantly augmented in peripheral blood, with plasma-
159 EVs showing enrichment for miRNA-126 and the integrin VCAM-1 (24, 29). In
160 agreement with our previous findings, patients with AMI had significantly more
161 plasma EVs at time of presentation ($24.3 \times 10^8 \pm 25.7$ EV / mL) versus a 6 month
162 follow-up measurement ($11.0 \times 10^8 \pm 12.5$ EV / mL, $P < 0.01$) but they exhibited a
163 similar EV size distribution profile, with a significant elevation in EVs in the size
164 range 100-200 nm diameter (**Figure 2A/B**). Plasma EV number at presentation was
165 significantly correlated with the extent of ischaemic injury as determined by T2-
166 weighted MRI ($R^2=0.459$, $P=0.006$) (**Figure 2C**) and with the extent of myocardial
167 scarring as determined by LGE at 6 months post-AMI ($R^2=0.423$, $P=0.009$) (**Figure**
168 **2D**). We also found a highly significant relationship between plasma-EV number and
169 peripheral blood neutrophil number ($R^2=0.753$, $P < 0.001$) at time of presentation
170 (**Figure 2E**), consistent with a possible role for plasma-EVs in neutrophil mobilisation
171 post-AMI.

172

173 **EC-EVs are enriched for miRNA-126**

174 In AMI, the total EV pool is enriched for EVs bearing VCAM-1 (24). Endothelial cells
175 are activated in AMI (32) and express VCAM-1 in response to ischaemia *in vivo* (33)

176 and to pro-inflammatory cytokines such as tumour necrosis factor- α (TNF- α) *in vitro*
177 (34). In order to probe the function of EVs-derived exclusively from activated
178 endothelial cells we studied primary human umbilical cord vein endothelial cells *in*
179 *vitro*. Compared with basal conditions, treatment of endothelial cells with pro-
180 inflammatory TNF- α activated endothelial cells as evidenced by enhanced VCAM-1
181 protein expression ($P < 0.001$) (Figure 3 A) and increased EV production ($P < 0.001$)
182 (**Figure 3B/C**), with a significant increase in small EVs, of similar size range (100-
183 200 nm) to those found to increase in patients with AMI. EC-EVs displayed typical
184 EV morphology (**Figure 3D/E**), the EV-protein marker CD9 (**Figure 3F**) and were
185 positive for endothelial nitric oxide synthase (eNOS). EV-depleted cell culture
186 supernatants and cell culture media that had not been exposed to cells were
187 negative for CD9 and eNOS, confirming robust EC-EV generation and isolation. EC-
188 EV preparations were negative for histone and mitochondrial markers of cellular
189 contamination, which were readily detected in endothelial cell pellets but not in
190 isolated EC-EVs or in EV-depleted cell culture supernatants (**Figure 3F**).

191 EC-EVs derived from pro-inflammatory stimulations show significant enrichment for
192 miRNA-126-3p ($P < 0.01$) (**Figure 3G**) and miRNA-126-5p ($P < 0.01$) (**Figure 3H**),
193 consistent with previous observations of changes in miRNA, measured in the
194 unselected EV pool, following AMI (24).

195

196 **miRNA-126-mRNA targets cluster selectively in neutrophil motility pathways**

197 To explore the potential role of EC-EV-miRNA-126 we employed *in silico*
198 bioinformatics techniques. We curated miRNA-126 putative mRNA target genes from
199 3 different miRNA-mRNA target prediction databases for human and the mouse. Our

200 curated lists comprised targets from TargetScanHuman, TargetScanMouse (35),
201 miRWalk (36) and miRDB (37).

202 We determined whether the mRNAs putatively regulated by miRNA-126 for the
203 human, mouse or the overlap gene set (targeted in both the human and mouse)
204 (**Figure 3I/3J and Supplementary Table 1/2**) were present in Gene Ontology (GO)
205 terms for neutrophil function. miRNA-126-putative-mRNA targets were significantly
206 overrepresented when compared by Fisher's exact test to neutrophil pathway GO
207 terms for neutrophil migration (GO: GO1990266) in the human ($P < 0.001$), the
208 mouse ($P < 0.001$) and the overlap gene set ($P < 0.001$) (**Supplementary Table 3**).
209 Similarly, miRNA-126-putative-mRNA targets were significantly overrepresented
210 when compared to the neutrophil pathway GO term for neutrophil chemotaxis (GO:
211 GO0030593) in the human ($P < 0.001$), the mouse ($P < 0.001$) and the overlap gene
212 set ($P < 0.001$) (**Supplementary Table 3**). Whereas, other neutrophil GO terms such
213 as neutrophil mediated killing of a fungus (GO: GO0070947), neutrophil clearance
214 (GO: GO0097350) and regulation of neutrophil mediated cytotoxicity (GO: 0070948)
215 were not enriched (**Supplementary Table 3**), suggesting a possible role for EC-EV-
216 miRNA-126 in orchestrating processes related to neutrophil mobilisation post-AMI.

217

218 **AMI alters neutrophil transcriptomes**

219 To determine whether neutrophil transcriptomes are altered post-AMI we obtained
220 peripheral blood neutrophils from newly recruited patients presenting with STEMI (N
221 = 3) and non-STEMI (NSTEMI) control patients (N = 3) at time of presentation and
222 matched-control samples one month later. STEMI patients had a greater number of
223 differentially expressed genes at time of presentation vs NSTEMI control patients
224 (STEMI 933 genes vs NSTEMI 8 genes) (**Figure 4A-C**). Differentially expressed
225 neutrophil transcriptomes in STEMI patients were determined by Gene Set
226 Enrichment Analysis (GSEA) to be positively enriched at time of presentation for
227 inflammatory pathways, including TNF- α signalling via NF- κ B (P<0.001),
228 inflammatory response (P<0.001) and interleukin-6 (IL-6) signalling via JAK-STAT3
229 (P<0.001) (**Figure 4D**).

230 To further understand the potential target pathways for the differentially enriched
231 genes in blood neutrophils following AMI we used GO term enrichment analysis and
232 ranked by false discovery rate (FDR)-adjusted p-values. GO analysis showed that
233 differentially expressed neutrophil genes at the time of presentation favoured
234 pathways for signal recognition particle (SRP)-dependent co-translational protein
235 targeting to membrane (GO:0006614) (P<0.001) and co-translational protein
236 targeting to membrane (GO:0006613) (P<0.001) (**Supplementary Table 4**).
237 Similarly, we used Reactome pathway analysis (38) to further explore target
238 pathways for the differentially enrichment genes at the time of presentation and
239 found SRP-dependent co-translational protein targeting to membrane (R-HSA-
240 1799339) (P<0.001) and neutrophil degranulation (R-HSA-6798695) (P<0.001) to be
241 significantly enriched (**Supplementary Table 4**).

242 Next, we used single cell (sc)-RNA-sequencing data to determine whether neutrophil
243 populations in the peripheral blood of mice subjected to AMI exhibited similar
244 transcriptomic alterations prior to recruitment to the heart. We found differential
245 enrichment in neutrophil populations in the blood following AMI (39), which favoured
246 GO terms for neutrophil aggregation (GO:0070488) (**Supplementary Table 5 and 6**)
247 ($P<0.05$), platelet activation (GO:0030168) ($P<0.001$) (**Supplementary Table 7**) and
248 Reactome pathways for SRP-dependent co-translational protein targeting to
249 membrane (R-HSA-1799339) ($P<0.001$) (**Supplementary Table 5 and 6**) ($P<0.001$)
250 and platelet activation, signalling and aggregation (R-HSA-76002) ($P<0.001$)
251 (**Supplementary Table 7**).

252 These analyses show that in both human and mouse neutrophils transcription is
253 differentially regulated in AMI. We further explored commonality between the human
254 and the mouse transcriptome response following AMI using GO terms (biological
255 process, molecular function and cellular component) and Reactome pathways
256 analysis. There were significant overlaps between the genes that are differentially
257 expressed following AMI in the blood of the human and the mouse ($P<0.001$)
258 (**Supplementary Table 8**) and significant similarity in target pathways between the
259 human and mouse (**Supplementary Table 9**), demonstrating that patterns of gene
260 expression are conserved and occur *prior* to recruitment to the injured heart. We
261 ranked the significant comparisons by size of their intersect and found that sc-RNA-
262 sequencing mouse blood neutrophil populations shared 38% similarity ($P<0.001$) and
263 37% similarity ($P<0.001$), respectively, to target pathways in human neutrophils
264 following AMI (**Supplementary Table 9**).

265

266 **miRNA-126-mRNA targets are overrepresented in neutrophil transcriptomes**
267 **following AMI**

268 Human miRNA-126-mRNA targets were significantly overrepresented in human
269 neutrophil transcriptomes at the time of injury ($P < 0.05$) (**Supplementary Table 10**).

270 There was no association between the differentially expressed genes in the mouse
271 blood neutrophil sc-RNA-sequencing populations and miRNA-126-mRNA targets
272 (**Supplementary Table 10**), but neutrophils within the myocardium displayed
273 differential enrichment for miRNA-126-mRNA targets (**Supplementary Table 10**).

274 There was significant enrichment for miRNA-126-mRNA targets from the human,
275 mouse and the overlap lists ($P < 0.001$), consistent with a role for miRNA-126 in
276 regulating neutrophil gene expression following AMI.

277 To test the functional significance of these findings, we treated wild-type mice with
278 an antagomiR for miRNA-126 ($n = 5$) or a scramble control ($n = 7$) prior to induction
279 of experimental AMI to assess the role of miRNA-126 on infarct size (**Figure 4E**) and
280 found a 12% reduction in infarct size in animals that received the miRNA-126
281 antagomir versus the scramble control ($P < 0.01$) (**Figure 4F**).

282

283 **EC-EVs localise to the spleen**

284 These accumulating data suggest that EC-EVs, enriched for miRNA-126 and VCAM-
285 1 provide an 'ischaemia signal' to neutrophils in the spleen, resulting in mobilisation
286 and transcriptional activation. Accordingly, we tested whether EC-EV localised to the
287 spleen after intravenous injection and whether there were consequent alterations in
288 neutrophil-associated chemokine gene and protein expression. Primary mouse and
289 human endothelial cells release more EVs following inflammatory stimulation (24)

290 and hypoxia (40). In agreement with these data and our previous observations,
291 mouse sEND.1 endothelial cells produced EV under basal conditions and released
292 significantly more EVs after pro-inflammatory stimulation with TNF- α ($P < 0.001$)
293 (**Figure 5A/B**) (24). We confirmed endothelial cell activation by TNF- α by probing for
294 VCAM-1 protein and found significantly more protein ($P < 0.001$) (**Figure 3C**). EC-EVs
295 displayed typical EV morphology (**Figure 5D/E**), EV-protein markers ALIX, TSG101
296 and CD9 (**Figure 5F**) and were positive for eNOS and VCAM-1. EV-depleted cell
297 culture supernatants and cell culture media that had not been exposed to cells were
298 negative for ALIX, TSG101, CD9, eNOS and VCAM-1, confirming robust EC-EV
299 isolation. EC-EVs derived from pro-inflammatory stimulations showed significant
300 enrichment for miRNA-126-3p ($P < 0.001$) (**Figure 5G**) and miRNA-126-5p ($P < 0.01$)
301 (**Figure 5H**), indicating similarities in the EC-EV response between human and
302 mouse endothelial cells. We labelled the mouse EC-EV by transfection with non-
303 mammalian miRNA-39, which belongs to *C. elegans* and allows quantitative tracing
304 of EVs *in vivo* (**Figure 6A**). This EC-EV labelling approach showed that EC-EVs
305 accumulated rapidly in the spleen and were detectable 2 hours, 6 hours ($P < 0.001$)
306 and 24 hours ($P < 0.001$) post-intravenous injection (**Figure 6A**).

307

308 **EC-EVs alter chemokine and protein expression in the spleen**

309 Informed by the earlier *in silico* studies suggesting regulation of neutrophil activation
310 and motility by miRNA-126, we hypothesised that EC-EV localisation in the spleen
311 would alter gene expression within spleen tissue, with a focus on CXC chemokine
312 and cytokine activity.

313 EC-EVs induced significantly altered mRNA in expression for *Cxcr2*, *Itag4*, *Gapdh*
314 (all, $P < 0.05$), *Il-1 β* , *Cxcl1* (both, $P < 0.01$), *Cxcr4* and *Il-6* (both, $P < 0.001$) post-EC-EV
315 injection (**Figure 6B**).

316 We further determined whether delivery of EC-EVs to the spleen altered chemokine
317 protein levels, including for the retention chemokine CXCL12 / SDF-1. In the same
318 mice we undertook a quantitative protein-detection array for 25 different proteins that
319 influence neutrophil function, including CXCL12 / SDF-1 , CCL2 (41) and CCL3 (42),
320 which are known miRNA-126-mRNA targets and CCL27/ CCL28, which are
321 predicted miRNA-126-mRNA targets. There were significant reductions in
322 6CKine/CCL21 ($P < 0.01$), BLC/CXCL13 ($P < 0.05$), chemerin/retinoic acid receptor
323 responder protein 2 (RARRES2) ($P < 0.01$), IL-16 ($P < 0.05$), MCP-5/CCL12 ($P < 0.05$)
324 and CXCL12 / SDF-1. ($P < 0.05$) (**Figure 6C**). These findings are consistent with a
325 role for EC-EV-miRNA-126 in silencing genes involved in cell retention.

326

327 **Endothelial cell derived EVs mobilise neutrophils from the spleen**

328 Given the effects of the EC-EVs derived from TNF- α activated cells on gene
329 expression and silencing of retention chemokines, we injected EC-EVs, derived from
330 TNF- α activated endothelial cells, intravenously into healthy wild-type mice vs sham
331 injection (**Figure 7A**). Flow cytometry (Live, CD45⁺, CD11b⁺, Ly6G⁺) showed that
332 EC-EVs significantly increased the number of circulating peripheral blood neutrophils
333 (**Figure 7B**), and simultaneously lowered splenic-neutrophil numbers in the same
334 mice (**Figure 7B**), confirming splenic neutrophil mobilisation induced by EC-EV.
335 Consistent with our observations in AMI we found that EC-EVs mediated greater
336 neutrophil mobilisation from the spleen ($P < 0.001$) than from the bone marrow

337 **(Figure 7C)**. As in the context of AMI, there was no alteration in CD62L/L-selectin
338 expression in blood neutrophils **(Figure 7D)**.

339

340 **EC-EV VCAM-1 mediates neutrophil mobilisation**

341 Plasma EVs present VCAM-1 on their surface **(Figure 8A)** and the number of
342 VCAM-1 positive EVs increases after AMI (24). Similarly, endothelial cells in culture
343 produce EVs enriched for VCAM-1 following pro-inflammatory stimulation **(Figure**
344 **5E)**. Given its well-established role in mediating interactions between activated
345 vascular endothelium and circulating leukocytes, we hypothesised that VCAM-1 on
346 EC-EVs might perform the converse role by mediating the capture of circulating EC-
347 EVs by static neutrophils in the spleen. We used CRISPR-Cas9 base editing of
348 endothelial cells to produce VCAM-1 deficient EC-EVs by introducing a stop codon in
349 the VCAM-1 sequence. To confirm CRISPR-Cas9 editing of VCAM-1 from
350 endothelial cells we stimulated wild-type (WT) and VCAM-1 knock-out (KO) cells with
351 TNF- α . WT mouse endothelial cells expressed more VCAM-1 following inflammatory
352 stimulation ($P < 0.001$) **(Figure 8B/C)**, whereas VCAM-1 KO cells did not express
353 VCAM-1, confirming successful CRISPR-Cas9 base editing in endothelial cells.
354 VCAM-1 KO cells released EC-EV under basal conditions similar to WT cells **(Figure**
355 **8D/E)** but VCAM-1 KO endothelial cells did not release more EVs following
356 inflammatory stimulation with TNF- α **(Figure 8D/E)**. WT and VCAM-1 KO EC-EV
357 were positive for EV-markers TSG101 and CD9 but only WT inflammatory derived
358 EC-EVs were positive for VCAM-1 **(Figure 8F)**. EC-EVs derived from either TNF- α
359 activated WT or TNF- α activated VCAM-1 KO cells were injected into healthy, wild-
360 type mice at the same concentration (1×10^9 / mL EC-EVs). Using the miRNA-39-3p

361 labelling technique (described above) we found that VCAM-1 deficient EC-EVs and
362 WT EC-EV accumulate in the spleen at similar levels (**Figure 8G**), but VCAM-1
363 deficient EC-EVs did not induce alteration in gene expression that were comparable
364 to WT EC-EVs responses in the spleen for *Il-6* ($P<0.001$), *Il-1 β* ($P<0.05$) and *Cxcl1*
365 ($P<0.05$) (**Figure 8H**), suggesting alter signalling. Furthermore, deletion of VCAM-1
366 in EC-EVs prevented mobilisation of splenic neutrophils to peripheral blood when
367 compared to wild-type VCAM-1+ EC-EVs (**Figure 8I and 8J**).

368

369 **Discussion**

370 Mobilisation of neutrophils occurs rapidly after AMI in mice and humans (1, 3, 4) and
371 their number in peripheral blood correlates with the extent of myocardial injury (1-3).
372 The bone marrow has been regarded as the principal source for neutrophils that are
373 mobilised to peripheral blood after injury, because (i) it is the primary site for
374 granulopoiesis (8-10); (ii) it contains ample reserves of mature cells and; (iii)
375 releases neutrophils in response to injection of exogenous chemokines (12-16).
376 However, the divergent timings of neutrophil mobilisation (rapid) (1, 20) and
377 chemokine elevation (delayed) *in vivo* (17, 18, 43) suggest that additional processes
378 may be involved.

379 Here, we have identified a previously unknown mechanism by which ischemic injury
380 to the myocardium signals to mobilization of neutrophils from a splenic reserve. We
381 show that: (i) EC-EV generated under conditions of inflammation are enriched for
382 VCAM-1, miRNA-126-3p and miRNA-126-5p; (ii) EC-EVs are delivered to the
383 spleen, where they alter gene and protein expression; and (iii) induce the
384 mobilisation of splenic neutrophils to peripheral blood. Notably, (iv) these EC-EV
385 effects are dependent on VCAM-1. Furthermore, (v) we show that neutrophil
386 transcriptomes are differentially regulated following AMI, prior to entry into the
387 myocardium. (vi) Targets of miRNA-126 are significantly altered in neutrophil
388 transcriptomes post-AMI and (vii) administration of miRNA-126 antagomir
389 significantly reduces infarct size *in vivo*.

390 Mature neutrophils are held in large numbers in the haemopoietic cords through
391 interactions with the neutrophil receptors CXCR4 and CXCL12 (11, 44, 45). Loss of
392 CXCL12 induces an increase in peripheral blood neutrophils. Injection of

393 chemotactic factors (13), CXCL chemokines (12, 14) and G-CSF (15, 16) can drive
394 the rapid mobilisation of neutrophils across the sinusoidal endothelium through
395 alterations in CXCR4-CXCL12.

396 Scrutiny of the relative timings of cytokine elevation after ischaemic injury in relation
397 to neutrophil mobilisation does not support their role in this early mobilisation, since
398 both the onset and peaks in neutrophil mobilisation occur prior to those for cytokine
399 elevation (17, 18, 43). IL-8 injection mobilised neutrophils from the bone marrow
400 (13), but after reperfusion in AMI, even in blood from the coronary sinus (undiluted
401 myocardial effluent), the elevation is modest (0.1-fold) (18, 19). Furthermore, we
402 calculate that the absolute concentration based on these physiological
403 measurements is approximately 2-3 orders of magnitude less than the concentration
404 used to elicit neutrophil mobilisation in mice (14). Finally, neutrophils are the first
405 cells to arrive in the acutely injured tissue. Neutrophil depletion dampens plasma
406 chemokines levels following AMI (7) and in a mouse air pouch model (46). It is not
407 clear which other cells in the profoundly ischaemic myocardium could be capable of
408 the rapid synthesis of chemokines, that would be of sufficient magnitude to mediate
409 neutrophil mobilisation from a remote site such as the bone marrow. The
410 sympathetic nervous system is also activated following AMI and mobilises
411 hematopoietic stem cells (HSCs) from the bone marrow (47). However, HSCs are
412 immature cells unlike terminally differentiated neutrophils and blood numbers of
413 HSCs do not peak until >6 hours post-AMI, subsequent to the increase in peripheral
414 blood neutrophils.

415 By contrast, numerous studies have shown that hypoxia promotes the rapid (<30
416 minutes) release of EVs by endothelial cells (40). We show that activated endothelial
417 cells in culture liberate large amounts of EV that contain VCAM-1 in their

418 membranes. Using CRISPR/Cas9 genome base editing of cultured endothelial cells,
419 we generated VCAM-1-deficient EV and showed that while VCAM-1 was not
420 essential for splenic localisation, its absence removed the ability of EV to provoke
421 the rapid mobilisation of neutrophils. Importantly, EVs are taken up rapidly and
422 selectively by the spleen where they become locally concentrated (24, 48), unlike
423 chemokines, which have a systemic effect.

424 Following injury to the myocardium there is a marked increase in VCAM-1-bearing-
425 EVs. VCAM-1 is a glycoprotein, which is expressed on activated endothelium and
426 has a well-established role in the recruitment of circulating leukocytes by binding
427 integrins (31, 49, 50), including CD49d (51) and CD11b/CD18 (52). Therefore, our
428 findings suggest an efficient signalling system, in which neutrophils are activated and
429 mobilised by engaging VCAM-1-bearing EVs that are taken up in the spleen, having
430 been released remotely from activated endothelium. A subsequent interaction
431 between neutrophils in circulation and static VCAM-1 on activated endothelial cells
432 mediates their recruitment to the original site of injury.

433 The recruitment of neutrophils to the injured myocardium is an essential step in
434 tissue response to injury and repair (1, 7, 20) and thus modulating the neutrophil
435 response raises possibilities for immuno-modulatory interventions in selected
436 inflammatory pathologies, including AMI. Peripheral blood neutrophils are elevated at
437 time of presentation with AMI in patients and rapidly increase in peripheral blood
438 following AMI in mice. Here, we show that splenic-neutrophils are rapidly mobilised
439 to peripheral blood by EC-EV bearing VCAM-1. These findings complement the
440 current paradigm in which neutrophils are liberated from bone marrow reserves
441 through elevations in blood chemokines. We demonstrate a novel and efficient
442 signalling mechanism between the injured heart microvasculature and the spleen.

443 Endothelial cells are ideally placed for the rapid release of EVs to peripheral blood
444 during ischemia. EV clearance is rapid and predominately to the spleen, which
445 contains neutrophils in the sup-capsular red pulp. Precisely how neutrophils are
446 retained in the spleen is not known, but our findings suggest that local chemokine
447 signalling may be important, as delivery of endothelial cell derived EVs rich in
448 miRNA-126 downregulates retention chemokines, including the miRNA-126 target
449 CXCL12, and induces expression of neutrophil mobilisation signals, namely CXCL1.
450 Importantly, we show that these processes are dependent on EV-VCAM-1, an
451 integrin with a well-documented role in immune cell recruitment. Furthermore, we
452 make a new observation that peripheral blood neutrophils are transcriptionally
453 activated prior to recruitment to the injured myocardium, with a bias towards miRNA-
454 126-mRNA targets. Our bioinformatics analysis revealed SRP-dependent co-
455 translational protein targeting to membrane as the most significantly enriched
456 pathway that was conserved between the human and the mouse blood neutrophils
457 following AMI. SRP is necessary for transferring newly synthesised nascent proteins
458 from the ribosome, which are destined for cellular excretion. SRP monoallelic
459 mutations induce a congenital blood neutropenia, possibly due to an increase in
460 susceptibility of neutrophils to apoptosis and the unfolded protein response (53, 54).
461 A significant enrichment for the universally conserved SRP supports our conclusion
462 that neutrophils are transcriptionally active prior to recruitment to the injured heart.
463 Targeting SRP may open novel opportunities to target neutrophil transcriptomes
464 prior to tissue recruitment to modulate their survival, function and phenotype, thereby
465 protecting injured tissues from pro-inflammatory neutrophil mediated damage.

466 In conclusion, we demonstrate that the injured myocardium can rapidly mobilise
467 splenic neutrophils through generation and release of EC-EVs that bear VCAM-1.

468 These findings provide novel insights into how neutrophils are mobilised to
469 peripheral blood following ischaemic injury, without the need for immediate
470 generation and release of chemokines. EVs are decorated in surface proteins and
471 integrins, which allows them to interact with cells and home to specific sites (55, 56).
472 A functionally efficient reciprocity may operate, in which VCAM-1, on endothelial cell-
473 derived EVs is required for the mobilisation of splenic neutrophils, complementing
474 the known role of static VCAM-1 in the recruitment of circulating neutrophils to
475 activated endothelium. Neutrophils are the first cells recruited to the ischemic
476 myocardium and are a major source of chemokines (7). Thus, the well-established
477 mobilisation of neutrophils from bone marrow reserves in response to chemokines
478 (12-16) represent a secondary response, which is consistent with the time course of
479 earlier reports and with our observations that there is no rapid bone marrow
480 mobilisation in the early phase.

481 We have shown proof of concept that genetic manipulation can alter EV properties in
482 functionally important ways. Immunomodulation of the neutrophil and monocyte
483 response to AMI using EV vectors may provide therapeutic opportunities in AMI.

484

485 **Materials and Methods**

486 Acute myocardial infarction patients

487 All clinical investigations were conducted in accordance with the Declaration of
488 Helsinki. The Oxfordshire Research Ethics Committee (references 08/H0603/41 and
489 11/SC/0397) approved human clinical cohort protocols. All patients provided
490 informed written consent for inclusion in the study.

491

492 LAD ligation model

493 All animal procedures were approved by an ethical review committee at the
494 University of Oxford or NYU Lagone Health. UK experimental interventions were
495 carried out by UK Home Office personal licence holders under the authority of a
496 Home Office project licence.

497

498 Further experimental details are provided in the supplementary methods.

499

500 Data Availability

501 RNA Sequencing data are deposited at Gene Expression Omnibus. *Pending*
502 accession number.

503

504 Statistical analysis

505 All values are group mean \pm standard deviation (s.d.). Paired and unpaired two-tailed
506 student's t test was used to compare 2 groups, a one-way or two-way analysis of
507 variance (ANOVA) or mixed model effects with post-hoc Bonferroni correction was
508 used to compare multiple group (>2) means with one, two or more independent
509 variables. *p* values <0.05 were considered significant. Hierarchical clustering
510 analysis and generation of heatmap plots was performed using the pheatmap R
511 package v1.0.12.

512

513

514

515 **References**

- 516 1. M. J. Schloss, M. Horckmans, K. Nitz, J. Duchene, M. Drechsler, K. Bidzhekov, C.
517 Scheiermann, C. Weber, O. Soehnlein, S. Steffens, The time-of-day of myocardial infarction
518 onset affects healing through oscillations in cardiac neutrophil recruitment. *EMBO Mol Med*
519 **8**, 937-948 (2016).
- 520 2. T. M. Guo, B. Cheng, L. Ke, S. M. Guan, B. L. Qi, W. Z. Li, B. Yang, Prognostic Value of
521 Neutrophil to Lymphocyte Ratio for In-hospital Mortality in Elderly Patients with Acute
522 Myocardial Infarction. *Curr Med Sci* **38**, 354-359 (2018).
- 523 3. T. Kong, T. H. Kim, Y. S. Park, S. P. Chung, H. S. Lee, J. H. Hong, J. W. Lee,
524 J. S. You, I. Park, Usefulness of the delta neutrophil index to predict 30-day
525 mortality in patients with ST segment elevation myocardial infarction.
526 *Scientific reports* **7**, 15718 (2017).
- 527 4. G. Sreejit, A. Abdel-Latif, B. Athmanathan, R. Annabathula, A. Dhyani, S. K.
528 Noothi, G. A. Quaife-Ryan, A. Al-Sharea, G. Pernes, D. Dragoljevic, H. Lal, K.
529 Schroder, B. Y. Hanaoka, C. Raman, M. B. Grant, J. E. Hudson, S. S. Smyth,
530 E. R. Porrello, A. J. Murphy, P. R. Nagareddy, Neutrophil-Derived S100A8/A9
531 Amplify Granulopoiesis After Myocardial Infarction. *Circulation* **141**, 1080-
532 1094 (2020).
- 533 5. S. Chia, J. T. Nagurney, D. F. Brown, O. C. Raffel, F. Bamberg, F. Senatore,
534 F. J. Wackers, I. K. Jang, Association of leukocyte and neutrophil counts with
535 infarct size, left ventricular function and outcomes after percutaneous
536 coronary intervention for ST-elevation myocardial infarction. *The American*
537 *journal of cardiology* **103**, 333-337 (2009).
- 538 6. H. Lorchner, J. Poling, P. Gajawada, Y. Hou, V. Polyakova, S. Kostin, J. M.
539 Adrian-Segarra, T. Boettger, A. Wietelmann, H. Warnecke, M. Richter, T.

- 540 Kubin, T. Braun, Myocardial healing requires Reg3beta-dependent
541 accumulation of macrophages in the ischemic heart. *Nature medicine* **21**, 353-
542 362 (2015).
- 543 7. M. Horckmans, L. Ring, J. Duchene, D. Santovito, M. J. Schloss, M.
544 Drechsler, C. Weber, O. Soehnlein, S. Steffens, Neutrophils orchestrate post-
545 myocardial infarction healing by polarizing macrophages towards a reparative
546 phenotype. *European Heart Journal* **38**, 187-197 (2016).
- 547 8. M. Evrard, I. W. H. Kwok, S. Z. Chong, K. W. W. Teng, E. Becht, J. Chen, J.
548 L. Sieow, H. L. Penny, G. C. Ching, S. Devi, J. M. Adrover, J. L. Y. Li, K. H.
549 Liong, L. Tan, Z. Poon, S. Foo, J. W. Chua, I. H. Su, K. Balabanian, F.
550 Bachelerie, S. K. Biswas, A. Larbi, W. Y. K. Hwang, V. Madan, H. P. Koeffler,
551 S. C. Wong, E. W. Newell, A. Hidalgo, F. Ginhoux, L. G. Ng, Developmental
552 Analysis of Bone Marrow Neutrophils Reveals Populations Specialized in
553 Expansion, Trafficking, and Effector Functions. *Immunity* **48**, 364-379 e368
554 (2018).
- 555 9. Y. P. Zhu, L. Padgett, H. Q. Dinh, P. Marcovecchio, A. Blatchley, R. Wu, E.
556 Ehinger, C. Kim, Z. Mikulski, G. Seumois, A. Madrigal, P. Vijayanand, C. C.
557 Hedrick, Identification of an Early Unipotent Neutrophil Progenitor with Pro-
558 tumoral Activity in Mouse and Human Bone Marrow. *Cell Rep* **24**, 2329-2341
559 e2328 (2018).
- 560 10. M. Horckmans, M. Bianchini, D. Santovito, R. T. A. Megens, J. Y. Springael, I.
561 Negri, M. Vacca, M. Di Eusano, A. Moschetta, C. Weber, J. Duchene, S.
562 Steffens, Pericardial Adipose Tissue Regulates Granulopoiesis, Fibrosis, and
563 Cardiac Function After Myocardial Infarction. *Circulation* **137**, 948-960 (2018).

- 564 11. R. C. Furze, S. M. Rankin, Neutrophil mobilization and clearance in the bone
565 marrow. *Immunology* **125**, 281-288 (2008).
- 566 12. C. Martin, P. C. E. Burdon, G. Bridger, J. C. Gutierrez-Ramos, T. J. Williams,
567 S. M. Rankin, Chemokines acting via CXCR2 and CXCR4 control the release
568 of neutrophils from the bone marrow and their return following senescence.
569 *Immunity* **19**, 583-593 (2003).
- 570 13. T. Terashima, D. English, J. C. Hogg, S. F. van Eeden, Release of
571 polymorphonuclear leukocytes from the bone marrow by interleukin-8. *Blood*
572 **92**, 1062-1069 (1998).
- 573 14. M. A. Jagels, T. E. Hugli, Neutrophil chemotactic factors promote
574 leukocytosis. A common mechanism for cellular recruitment from bone
575 marrow. *Journal of immunology* **148**, 1119-1128 (1992).
- 576 15. C. L. Semerad, F. L. Liu, A. D. Gregory, K. Stumpf, D. C. Link, G-CSF is an
577 essential regulator of neutrophil trafficking from the bone marrow to the blood.
578 *Immunity* **17**, 413-423 (2002).
- 579 16. A. Köhler, K. De Filippo, M. Hasenberg, C. van den Brandt, E. Nye, M. P.
580 Hosking, T. E. Lane, L. Männ, R. M. Ransohoff, A. E. Hauser, O. Winter, B.
581 Schraven, H. Geiger, N. Hogg, M. Gunzer, G-CSF-mediated thrombopoietin
582 release triggers neutrophil motility and mobilization from bone marrow via
583 induction of Cxcr2 ligands. *Blood* **117**, 4349-4357 (2011).
- 584 17. A. Deten, H. C. Volz, W. Briest, H. G. Zimmer, Cardiac cytokine expression is
585 upregulated in the acute phase after myocardial infarction. Experimental
586 studies in rats. *Cardiovascular research* **55**, 329-340 (2002).

- 587 18. F. J. Neumann, I. Ott, M. Gawaz, G. Richardt, H. Holzapfel, M. Jochum, A.
588 Schomig, Cardiac release of cytokines and inflammatory responses in acute
589 myocardial infarction. *Circulation* **92**, 748-755 (1995).
- 590 19. N. Marx, F.-J. Neumann, I. Ott, M. Gawaz, W. Koch, T. Pinkau, A. Schömig,
591 Induction of Cytokine Expression in Leukocytes in Acute Myocardial
592 Infarction. *Journal of the american college of cardiology* **30**, 165-170 (1997).
- 593 20. M. Horckmans, L. Ring, J. Duchene, D. Santovito, M. J. Schloss, M.
594 Drechsler, C. Weber, O. Soehnlein, S. Steffens, Neutrophils orchestrate post-
595 myocardial infarction healing by polarizing macrophages towards a reparative
596 phenotype. *Eur Heart J* **38**, 187-197 (2017).
- 597 21. I. Puga, M. Cols, C. M. Barra, B. He, L. Cassis, M. Gentile, L. Comerma, A.
598 Chorny, M. Shan, W. Xu, G. Magri, D. M. Knowles, W. Tam, A. Chiu, J. B.
599 Bussel, S. Serrano, J. A. Lorente, B. Bellosillo, J. Lloreta, N. Juanpere, F.
600 Alameda, T. Baro, C. D. de Heredia, N. Toran, A. Catala, M. Torrebadell, C.
601 Fortuny, V. Cusi, C. Carreras, G. A. Diaz, J. M. Blander, C. M. Farber, G.
602 Silvestri, C. Cunningham-Rundles, M. Calvillo, C. Dufour, L. D. Notarangelo,
603 V. Lougaris, A. Plebani, J. L. Casanova, S. C. Ganal, A. Diefenbach, J. I.
604 Arostegui, M. Juan, J. Yague, N. Mahlaoui, J. Donadieu, K. Chen, A. Cerutti,
605 B cell-helper neutrophils stimulate the diversification and production of
606 immunoglobulin in the marginal zone of the spleen. *Nat Immunol* **13**, 170-180
607 (2011).
- 608 22. J. F. Deniset, B. G. Surewaard, W. Y. Lee, P. Kubes, Splenic Ly6G(high)
609 mature and Ly6G(int) immature neutrophils contribute to eradication of S.
610 pneumoniae. *J Exp Med* **214**, 1333-1350 (2017).

- 611 23. F. K. Swirski, M. Nahrendorf, M. Etzrodt, M. Wildgruber, V. Cortez-Retamozo,
612 P. Panizzi, J. L. Figueiredo, R. H. Kohler, A. Chudnovskiy, P. Waterman, E.
613 Aikawa, T. R. Mempel, P. Libby, R. Weissleder, M. J. Pittet, Identification of
614 splenic reservoir monocytes and their deployment to inflammatory sites.
615 *Science* **325**, 612-616 (2009).
- 616 24. N. Akbar, J. E. Digby, T. J. Cahill, A. N. Tavaré, A. L. Corbin, S. Saluja, S.
617 Dawkins, L. Edgar, N. Rawlings, K. Ziberna, E. McNeill, S. Oxford Acute
618 Myocardial Infarction, E. Johnson, A. A. Aljabali, R. A. Dragovic, M. Rohling,
619 T. G. Belgard, I. A. Udalova, D. R. Greaves, K. M. Channon, P. R. Riley, D. C.
620 Anthony, R. P. Choudhury, Endothelium-derived extracellular vesicles
621 promote splenic monocyte mobilization in myocardial infarction. *JCI Insight* **2**,
622 7;2(17):e93344 (2017).
- 623 25. C. Thery, K. W. Witwer, E. Aikawa, M. J. Alcaraz, J. D. Anderson, R.
624 Andriantsitohaina, A. Antoniou, T. Arab, F. Archer, G. K. Atkin-Smith, D. C.
625 Ayre, J. M. Bach, D. Bachurski, H. Baharvand, L. Balaj, S. Baldacchino, N. N.
626 Bauer, A. A. Baxter, M. Bebawy, C. Beckham, A. Bedina Zavec, A.
627 Benmoussa, A. C. Berardi, P. Bergese, E. Bielska, C. Blenkiron, S. Bobis-
628 Wozowicz, E. Boilard, W. Boireau, A. Bongiovanni, F. E. Borrás, S. Bosch, C.
629 M. Boulanger, X. Breakefield, A. M. Breglio, M. A. Brennan, D. R. Brigstock,
630 A. Brisson, M. L. Broekman, J. F. Bromberg, P. Bryl-Gorecka, S. Buch, A. H.
631 Buck, D. Burger, S. Busatto, D. Buschmann, B. Bussolati, E. I. Buzas, J. B.
632 Byrd, G. Camussi, D. R. Carter, S. Caruso, L. W. Chamley, Y. T. Chang, C.
633 Chen, S. Chen, L. Cheng, A. R. Chin, A. Clayton, S. P. Clerici, A. Cocks, E.
634 Cocucci, R. J. Coffey, A. Cordeiro-da-Silva, Y. Couch, F. A. Coumans, B.
635 Coyle, R. Crescitelli, M. F. Criado, C. D'Souza-Schorey, S. Das, A. Datta

636 Chaudhuri, P. de Candia, E. F. De Santana, O. De Wever, H. A. Del Portillo,
637 T. Demaret, S. Deville, A. Devitt, B. Dhondt, D. Di Vizio, L. C. Dieterich, V.
638 Dolo, A. P. Dominguez Rubio, M. Dominici, M. R. Dourado, T. A. Driedonks,
639 F. V. Duarte, H. M. Duncan, R. M. Eichenberger, K. Ekstrom, S. El
640 Andaloussi, C. Elie-Caille, U. Erdbrugger, J. M. Falcon-Perez, F. Fatima, J. E.
641 Fish, M. Flores-Bellver, A. Forsonits, A. Frelet-Barrand, F. Fricke, G.
642 Fuhrmann, S. Gabrielsson, A. Gamez-Valero, C. Gardiner, K. Gartner, R.
643 Gaudin, Y. S. Ghossein, B. Giebel, C. Gilbert, M. Gimona, I. Giusti, D. C.
644 Goberdhan, A. Gorgens, S. M. Gorski, D. W. Greening, J. C. Gross, A.
645 Gualerzi, G. N. Gupta, D. Gustafson, A. Handberg, R. A. Haraszti, P.
646 Harrison, H. Hegyesi, A. Hendrix, A. F. Hill, F. H. Hochberg, K. F. Hoffmann,
647 B. Holder, H. Holthofer, B. Hosseinkhani, G. Hu, Y. Huang, V. Huber, S. Hunt,
648 A. G. Ibrahim, T. Ikezu, J. M. Inal, M. Isin, A. Ivanova, H. K. Jackson, S.
649 Jacobsen, S. M. Jay, M. Jayachandran, G. Jenster, L. Jiang, S. M. Johnson,
650 J. C. Jones, A. Jong, T. Jovanovic-Talisman, S. Jung, R. Kalluri, S. I. Kano, S.
651 Kaur, Y. Kawamura, E. T. Keller, D. Khamari, E. Khomyakova, A. Khvorova,
652 P. Kierulf, K. P. Kim, T. Kislinger, M. Klingeborn, D. J. Klinke, 2nd, M. Kornek,
653 M. M. Kosanovic, A. F. Kovacs, E. M. Kramer-Albers, S. Krasemann, M.
654 Krause, I. V. Kurochkin, G. D. Kusuma, S. Kuypers, S. Laitinen, S. M.
655 Langevin, L. R. Languino, J. Lannigan, C. Lasser, L. C. Laurent, G. Lavie, E.
656 Lazaro-Ibanez, S. Le Lay, M. S. Lee, Y. X. F. Lee, D. S. Lemos, M. Lenassi,
657 A. Leszczynska, I. T. Li, K. Liao, S. F. Libregts, E. Ligeti, R. Lim, S. K. Lim, A.
658 Line, K. Linnemannstons, A. Llorente, C. A. Lombard, M. J. Lorenowicz, A. M.
659 Lorincz, J. Lotvall, J. Lovett, M. C. Lowry, X. Loyer, Q. Lu, B. Lukomska, T. R.
660 Lunavat, S. L. Maas, H. Malhi, A. Marcilla, J. Mariani, J. Mariscal, E. S.

661 Martens-Uzunova, L. Martin-Jaular, M. C. Martinez, V. R. Martins, M. Mathieu,
662 S. Mathivanan, M. Maugeri, L. K. McGinnis, M. J. McVey, D. G. Meckes, Jr.,
663 K. L. Meehan, I. Mertens, V. R. Minciocchi, A. Moller, M. Moller Jorgensen, A.
664 Morales-Kastresana, J. Morhayim, F. Mullier, M. Muraca, L. Musante, V.
665 Mussack, D. C. Muth, K. H. Myburgh, T. Najrana, M. Nawaz, I. Nazarenko, P.
666 Nejsum, C. Neri, T. Neri, R. Nieuwland, L. Nimrichter, J. P. Nolan, E. N. Nolte-
667 't Hoen, N. Noren Hooten, L. O'Driscoll, T. O'Grady, A. O'Loghlen, T. Ochiya,
668 M. Olivier, A. Ortiz, L. A. Ortiz, X. Osteikoetxea, O. Ostergaard, M. Ostrowski,
669 J. Park, D. M. Pegtel, H. Peinado, F. Perut, M. W. Pfaffl, D. G. Phinney, B. C.
670 Pieters, R. C. Pink, D. S. Pisetsky, E. Pogge von Strandmann, I.
671 Polakovicova, I. K. Poon, B. H. Powell, I. Prada, L. Pulliam, P. Quesenberry,
672 A. Radeghieri, R. L. Raffai, S. Raimondo, J. Rak, M. I. Ramirez, G. Raposo,
673 M. S. Rayyan, N. Regev-Rudzki, F. L. Ricklefs, P. D. Robbins, D. D. Roberts,
674 S. C. Rodrigues, E. Rohde, S. Rome, K. M. Rouschop, A. Rughetti, A. E.
675 Russell, P. Saa, S. Sahoo, E. Salas-Huenuleo, C. Sanchez, J. A. Saugstad,
676 M. J. Saul, R. M. Schiffelers, R. Schneider, T. H. Schoyen, A. Scott, E.
677 Shahaj, S. Sharma, O. Shatnyeva, F. Shekari, G. V. Shelke, A. K. Shetty, K.
678 Shiba, P. R. Siljander, A. M. Silva, A. Skowronek, O. L. Snyder, 2nd, R. P.
679 Soares, B. W. Sodar, C. Soekmadji, J. Sotillo, P. D. Stahl, W. Stoorvogel, S.
680 L. Stott, E. F. Strasser, S. Swift, H. Tahara, M. Tewari, K. Timms, S. Tiwari, R.
681 Tixeira, M. Tkach, W. S. Toh, R. Tomasini, A. C. Torrecilhas, J. P. Tosar, V.
682 Toxavidis, L. Urbanelli, P. Vader, B. W. van Balkom, S. G. van der Grein, J.
683 Van Deun, M. J. van Herwijnen, K. Van Keuren-Jensen, G. van Niel, M. E.
684 van Royen, A. J. van Wijnen, M. H. Vasconcelos, I. J. Vechetti, Jr., T. D. Veit,
685 L. J. Vella, E. Velot, F. J. Verweij, B. Vestad, J. L. Vinas, T. Visnovitz, K. V.

- 686 Vukman, J. Wahlgren, D. C. Watson, M. H. Wauben, A. Weaver, J. P.
687 Webber, V. Weber, A. M. Wehman, D. J. Weiss, J. A. Welsh, S. Wendt, A. M.
688 Wheelock, Z. Wiener, L. Witte, J. Wolfram, A. Xagorari, P. Xander, J. Xu, X.
689 Yan, M. Yanez-Mo, H. Yin, Y. Yuana, V. Zappulli, J. Zarubova, V. Zekas, J. Y.
690 Zhang, Z. Zhao, L. Zheng, A. R. Zheutlin, A. M. Zickler, P. Zimmermann, A.
691 M. Zivkovic, D. Zocco, E. K. Zuba-Surma, Minimal information for studies of
692 extracellular vesicles 2018 (MISEV2018): a position statement of the
693 International Society for Extracellular Vesicles and update of the MISEV2014
694 guidelines. *J Extracell Vesicles* **7**, 1535750 (2018).
- 695 26. N. Akbar, V. Azzimato, R. P. Choudhury, M. Aouadi, Extracellular vesicles in
696 metabolic disease. *Diabetologia* **62**, 2179-2187 (2019).
- 697 27. J. P. G. Sluijter, S. M. Davidson, C. M. Boulanger, E. I. Buzás, D. P. V. de
698 Kleijn, F. B. Engel, Z. Giricz, D. J. Hausenloy, R. Kishore, S. Lecour, J. Leor,
699 R. Madonna, C. Perrino, F. Prunier, S. Sahoo, R. M. Schiffelers, R. Schulz, L.
700 W. Van Laake, K. Ytrehus, P. Ferdinandy, Extracellular vesicles in diagnostics
701 and therapy of the ischaemic heart: Position Paper from the Working Group
702 on Cellular Biology of the Heart of the European Society of Cardiology.
703 *Cardiovascular research* **114**, 19-34 (2018).
- 704 28. A. E. Russell, A. Sneider, K. W. Witwer, P. Bergese, S. N. Bhattacharyya, A.
705 Cocks, E. Cocucci, U. Erdbrugger, J. M. Falcon-Perez, D. W. Freeman, T. M.
706 Gallagher, S. Hu, Y. Huang, S. M. Jay, S. I. Kano, G. Lavieu, A. Leszczynska,
707 A. M. Llorente, Q. Lu, V. Mahairaki, D. C. Muth, N. Noren Hooten, M.
708 Ostrowski, I. Prada, S. Sahoo, T. H. Schoyen, L. Sheng, D. Tesch, G. Van
709 Niel, R. E. Vandenbroucke, F. J. Verweij, A. V. Villar, M. Wauben, A. M.
710 Wehman, H. Yin, D. R. F. Carter, P. Vader, Biological membranes in EV

- 711 biogenesis, stability, uptake, and cargo transfer: an ISEV position paper
712 arising from the ISEV membranes and EVs workshop. *J Extracell Vesicles* **8**,
713 1684862 (2019).
- 714 29. X. Loyer, I. Zlatanova, C. Devue, M. Yin, K. Y. Howangyin, P. Klaihmon, C. L.
715 Guerin, M. Kheloufi, J. Vilar, K. Zannis, B. K. Fleischmann, D. W. Hwang, J.
716 Park, H. Lee, P. Menasche, J. S. Silvestre, C. M. Boulanger, Intra-Cardiac
717 Release of Extracellular Vesicles Shapes Inflammation Following Myocardial
718 Infarction. *Circulation research* **123**, 100-106 (2018).
- 719 30. M. Cheng, J. Yang, X. Zhao, E. Zhang, Q. Zeng, Y. Yu, L. Yang, B. Wu, G. Yi,
720 X. Mao, K. Huang, N. Dong, M. Xie, N. A. Limdi, S. D. Prabhu, J. Zhang, G.
721 Qin, Circulating myocardial microRNAs from infarcted hearts are carried in
722 exosomes and mobilise bone marrow progenitor cells. *Nature*
723 *communications* **10**, 959 (2019).
- 724 31. E. A. Ross, M. R. Douglas, S. H. Wong, E. J. Ross, S. J. Curnow, G. B. Nash,
725 E. Rainger, D. Scheel-Toellner, J. M. Lord, M. Salmon, C. D. Buckley,
726 Interaction between integrin alpha9beta1 and vascular cell adhesion
727 molecule-1 (VCAM-1) inhibits neutrophil apoptosis. *Blood* **107**, 1178-1183
728 (2006).
- 729 32. N. Ruparelia, J. E. Digby, A. Jefferson, D. J. Medway, S. Neubauer, C. A.
730 Lygate, R. P. Choudhury, Myocardial infarction causes inflammation and
731 leukocyte recruitment at remote sites in the myocardium and in the renal
732 glomerulus. *Inflamm Res* **62**, 515-525 (2013).
- 733 33. A. M. Akhtar, J. E. Schneider, S. J. Chapman, A. Jefferson, J. E. Digby, K.
734 Mankia, Y. Chen, M. A. McAteer, K. J. Wood, R. P. Choudhury, In vivo
735 quantification of VCAM-1 expression in renal ischemia reperfusion injury using

- 736 non-invasive magnetic resonance molecular imaging. *PloS one* **5**, e12800
737 (2010).
- 738 34. L. Osborn, C. Hession, R. Tizard, C. Vassallo, S. Luhowskyj, G. Chirosso, R.
739 Lobb, Direct Expression Cloning of Vascular Cell-Adhesion Molecule-1, a
740 Cytokine-Induced Endothelial Protein That Binds to Lymphocytes. *Cell* **59**,
741 1203-1211 (1989).
- 742 35. V. Agarwal, G. W. Bell, J. W. Nam, D. P. Bartel, Predicting effective
743 microRNA target sites in mammalian mRNAs. *Elife* **4**, (2015).
- 744 36. C. Sticht, C. De La Torre, A. Parveen, N. Gretz, miRWalk: An online resource
745 for prediction of microRNA binding sites. *PloS one* **13**, e0206239 (2018).
- 746 37. W. Liu, X. Wang, Prediction of functional microRNA targets by integrative
747 modeling of microRNA binding and target expression data. *Genome Biol* **20**,
748 18 (2019).
- 749 38. B. Jassal, L. Matthews, G. Viteri, C. Gong, P. Lorente, A. Fabregat, K.
750 Sidiropoulos, J. Cook, M. Gillespie, R. Haw, F. Loney, B. May, M. Milacic, K.
751 Rothfels, C. Sevilla, V. Shamovsky, S. Shorser, T. Varusai, J. Weiser, G. Wu,
752 L. Stein, H. Hermjakob, P. D'Eustachio, The reactome pathway
753 knowledgebase. *Nucleic acids research* **48**, D498-D503 (2019).
- 754 39. E. Vafadarnejad, G. Rizzo, L. Krampert, P. Arampatzi, A. P. Arias-Loza, Y.
755 Nazzal, A. Rizakou, T. Knochenhauer, S. R. Bandi, V. A. Nugroho, D. J. J.
756 Schulz, M. Roesch, P. Alayrac, J. Vilar, J. S. Silvestre, A. Zerneck, A. E.
757 Saliba, C. Cochain, Dynamics of Cardiac Neutrophil Diversity in Murine
758 Myocardial Infarction. *Circulation research* **127**, e232-e249 (2020).

- 759 40. S. M. Davidson, J. A. Riquelme, Y. Zheng, J. M. Vicencio, S. Lavandero, D.
760 M. Yellon, Endothelial cells release cardioprotective exosomes that may
761 contribute to ischaemic preconditioning. *Scientific reports* **8**, 15885 (2018).
- 762 41. E. Arner, N. Mejhert, A. Kulyte, P. J. Balwierz, M. Pachkov, M. Cormont, S.
763 Lorente-Cebrian, A. Ehrlund, J. Laurencikiene, P. Heden, K. Dahlman-Wright,
764 J. F. Tanti, Y. Hayashizaki, M. Ryden, I. Dahlman, E. van Nimwegen, C. O.
765 Daub, P. Arner, Adipose tissue microRNAs as regulators of CCL2 production
766 in human obesity. *Diabetes* **61**, 1986-1993 (2012).
- 767 42. J. Agudo, A. Ruzo, N. Tung, H. Salmon, M. Leboeuf, D. Hashimoto, C.
768 Becker, L. A. Garrett-Sinha, A. Baccarini, M. Merad, B. D. Brown, The miR-
769 126-VEGFR2 axis controls the innate response to pathogen-associated
770 nucleic acids. *Nat Immunol* **15**, 54-62 (2014).
- 771 43. V. Rusinkevich, Y. Huang, Z.-y. Chen, W. Qiang, Y.-g. Wang, Y.-f. Shi, H.-t.
772 Yang, Temporal dynamics of immune response following prolonged
773 myocardial ischemia/reperfusion with and without cyclosporine A. *Acta*
774 *Pharmacologica Sinica* **40**, 1168-1183 (2019).
- 775 44. K. J. Eash, J. M. Means, D. W. White, D. C. Link, CXCR4 is a key regulator of
776 neutrophil release from the bone marrow under basal and stress
777 granulopoiesis conditions. *Blood* **113**, 4711-4719 (2009).
- 778 45. B. T. Suratt, J. M. Petty, S. K. Young, K. C. Malcolm, J. G. Lieber, J. A. Nick,
779 J. A. Gonzalo, P. M. Henson, G. S. Worthen, Role of the CXCR4/SDF-1
780 chemokine axis in circulating neutrophil homeostasis. *Blood* **104**, 565-571
781 (2004).
- 782 46. E. Garcia-Ramallo, T. Marques, N. Prats, J. Beleta, S. L. Kunkel, N.
783 Godessart, Resident cell chemokine expression serves as the major

- 784 mechanism for leukocyte recruitment during local inflammation. *J Immunol*
785 **169**, 6467-6473 (2002).
- 786 47. P. Dutta, G. Courties, Y. Wei, F. Leuschner, R. Gorbatov, C. S. Robbins, Y.
787 Iwamoto, B. Thompson, A. L. Carlson, T. Heidt, M. D. Majmudar, F.
788 Lasitschka, M. Etzrodt, P. Waterman, M. T. Waring, A. T. Chicoine, A. M. van
789 der Laan, H. W. Niessen, J. J. Piek, B. B. Rubin, J. Butany, J. R. Stone, H. A.
790 Katus, S. A. Murphy, D. A. Morrow, M. S. Sabatine, C. Vinegoni, M. A.
791 Moskowitz, M. J. Pittet, P. Libby, C. P. Lin, F. K. Swirski, R. Weissleder, M.
792 Nahrendorf, Myocardial infarction accelerates atherosclerosis. *Nature* **487**,
793 325-329 (2012).
- 794 48. S. C. Saunderson, A. C. Dunn, P. R. Crocker, A. D. McLellan, CD169
795 mediates the capture of exosomes in spleen and lymph node. *Blood* **123**, 208-
796 216 (2014).
- 797 49. J. V. Forrester, J. M. Lackie, Adhesion of neutrophil leucocytes under
798 conditions of flow. *Journal of cell science* **70**, 93-110 (1984).
- 799 50. Y. Taooka, J. Chen, T. Yednock, D. Sheppard, The integrin alpha9beta1
800 mediates adhesion to activated endothelial cells and transendothelial
801 neutrophil migration through interaction with vascular cell adhesion molecule-
802 1. *The Journal of cell biology* **145**, 413-420 (1999).
- 803 51. T. B. Issekutz, M. Miyasaka, A. C. Issekutz, Rat blood neutrophils express
804 very late antigen 4 and it mediates migration to arthritic joint and dermal
805 inflammation. *J Exp Med* **183**, 2175-2184 (1996).
- 806 52. A. C. Issekutz, L. Ayer, M. Miyasaka, T. B. Issekutz, Treatment of established
807 adjuvant arthritis in rats with monoclonal antibody to CD18 and very late
808 activation antigen-4 integrins suppresses neutrophil and T-lymphocyte

809 migration to the joints and improves clinical disease. *Immunology* **88**, 569-576
810 (1996).

811 53. C. Bellanné-Chantelot, B. Schmaltz-Panneau, C. Marty, O. Fenneteau, I.
812 Callebaut, S. Clauin, A. Docet, G.-L. Damaj, T. Leblanc, I. Pellier, C. Stoven,
813 S. Souquere, I. Antony-Debré, B. Beaupain, N. Aladjidi, V. Barlogis, F.
814 Bauduer, P. Bensaid, O. Boespflug-Tanguy, C. Berger, Y. Bertrand, L.
815 Carausu, C. Fieschi, C. Galambrun, A. Schmidt, H. Journal, F. Mazingue, B.
816 Nelken, T. C. Quah, E. Oksenhendler, M. Ouachée, M. Pasquet, V. Saada, F.
817 Suarez, G. Pierron, W. Vainchenker, I. Plo, J. Donadieu, Mutations in the
818 SRP54 gene cause severe congenital neutropenia as well as Shwachman-
819 Diamond-like syndrome. *Blood* **132**, 1318-1331 (2018).

820 54. Y. Mizoguchi, S. Hesse, M. Linder, N. Zietara, M. Lyszkiewicz, Y. Liu, M.
821 Tatematsu, P. Grabowski, K. Ahomaa, T. Jeske, S. Hollizeck, E. Rusha, M. K.
822 Saito, M. Kobayashi, Z. Alizadeh, Z. Pourpak, S. Iurian, N. Rezaei, E. Unal,
823 M. Drukker, B. Walzog, F. Hauck, J. Rappsilber, C. Klein, Defects in Signal
824 Recognition Particle (SRP) Components Reveal an Essential and Non-
825 Redundant Role for Granule Biogenesis and Differentiation of Neutrophil
826 Granulocytes. *Blood* **134**, 216-216 (2019).

827 55. A. Hoshino, B. Costa-Silva, T. L. Shen, G. Rodrigues, A. Hashimoto, M. Tesic
828 Mark, H. Molina, S. Kohsaka, A. Di Giannatale, S. Ceder, S. Singh, C.
829 Williams, N. Soplod, K. Uryu, L. Pharmer, T. King, L. Bojmar, A. E. Davies, Y.
830 Ararso, T. Zhang, H. Zhang, J. Hernandez, J. M. Weiss, V. D. Dumont-Cole,
831 K. Kramer, L. H. Wexler, A. Narendran, G. K. Schwartz, J. H. Healey, P.
832 Sandstrom, K. J. Labori, E. H. Kure, P. M. Grandgenett, M. A. Hollingsworth,
833 M. de Sousa, S. Kaur, M. Jain, K. Mallya, S. K. Batra, W. R. Jarnagin, M. S.

834 Brady, O. Fodstad, V. Muller, K. Pantel, A. J. Minn, M. J. Bissell, B. A. Garcia,
835 Y. Kang, V. K. Rajasekhar, C. M. Ghajar, I. Matei, H. Peinado, J. Bromberg,
836 D. Lyden, Tumour exosome integrins determine organotropic metastasis.
837 *Nature* **527**, 329-335 (2015).

838 56. G. Rodrigues, A. Hoshino, C. M. Kenific, I. R. Matei, L. Steiner, D. Freitas, H.
839 S. Kim, P. R. Oxley, I. Scandariato, I. Casanova-Salas, J. Dai, C. R. Badwe,
840 B. Gril, M. Tesic Mark, B. D. Dill, H. Molina, H. Zhang, A. Benito-Martin, L.
841 Bojmar, Y. Ararso, K. Offer, Q. LaPlant, W. Buehring, H. Wang, X. Jiang, T.
842 M. Lu, Y. Liu, J. K. Sabari, S. J. Shin, N. Narula, P. S. Ginter, V. K.
843 Rajasekhar, J. H. Healey, E. Meylan, B. Costa-Silva, S. E. Wang, S. Rafii, N.
844 K. Altorki, C. M. Rudin, D. R. Jones, P. S. Steeg, H. Peinado, C. M. Ghajar, J.
845 Bromberg, M. de Sousa, D. Pisapia, D. Lyden, Tumour exosomal CEMIP
846 protein promotes cancer cell colonization in brain metastasis. *Nat Cell Biol* **21**,
847 1403-1412 (2019).

848

849

850 **Acknowledgments**

851 **Statement of Contribution**

852 NA isolated, characterized, and utilized EVs in the described experiments and
853 performed western blots, RT-qPCR, chemokine arrays, analysis of infarcted hearts
854 and assisted with *in silico* bioinformatics. ATB, CL, EL, LE, GM, EM, CvS assisted
855 with experimentation. EEC, GJK and CvS undertook antagomiR experiments. ATB
856 performed bioinformatics analysis and generated transcriptome analysis graphs and
857 heat maps. ALC and DP prepared and analysed flow cytometry preparations. AC,

858 RD and EJ imaged EVs by TEM /Cryo-TEM. MGH performed some AMI surgeries.
859 TK and CB performed RNA sequencing. JR performed CRISPR-cas9 base editing of
860 endothelial cells. KJM, PR, KM and DCA led animal investigations. RC and KMC led
861 human AMI investigations. NA and RC conceived the study. All authors participated
862 in study design, coordination and helped to draft the manuscript. All authors have
863 seen the final version of the manuscript and approve of its submission.

864

865 The authors thank the staff at the Oxford Heart Centre for the clinical care of patients
866 recruited in the coordination of the OxAMI study. Phil Townsend and Steve
867 Woodhouse are gratefully acknowledged for general laboratory management. The
868 authors thank biomedical services staff for their expert care of mice used in this
869 study. The OxAMI study is supported by the British Heart Foundation (BHF; grant
870 CH/16/1/32013 to KMC), the BHF Centre of Research Excellence, Oxford
871 (RG/13/1/30181), the National Institute for Health Research Biomedical Research
872 Centre, Oxford and the and the Biomedical Sequencing Facility (BSF) at CeMM for
873 assistance with next-generation sequencing. See Supplemental Acknowledgments
874 for OxAMI details.

875

876 **Funding**

877 NA and RC acknowledge support by research grants from the British Heart
878 Foundation (BHF) Centre of Research Excellence, Oxford (NA and RC:
879 RE/13/1/30181), British Heart Foundation Project Grant (NA and RC:
880 PG/18/53/33895), the Tripartite Immunometabolism Consortium, Novo Nordisk
881 Foundation (RC: NNF15CC0018486), Oxford Biomedical Research Centre (BRC),

882 Nuffield Benefaction for Medicine and the Wellcome Institutional Strategic Support
883 Fund (ISSF) (NA), the National Institutes of Health (NIHR)
884 (R35HL135799,P01HL131478 (KJM) and T32HL098129 (CvS)) and the American
885 Heart Association (19CDA346300066 (CvS)). DRFC and GM acknowledge BBSRC
886 (BB/P006205/1). The views expressed are those of the author(s) and not necessarily
887 those of the NHS, the NIHR or the Department of Health

888

889 **Figures and Figure Legends**

890 **Figure 1. Human peripheral blood neutrophils correlate with the extent of**
891 **myocardial injury in AMI. A** Pearson's correlation of peripheral blood neutrophil
892 number ($10^9 / L$) in patients experiencing AMI significantly correlated with the extent
893 of myocardial injury (T2-weight MRI) and **B** LGE MRI 6-months post-AMI ($n = 15$). **C**
894 Schematic representation of mouse AMI and tissue harvesting for flow cytometry. **D**
895 Percentage of neutrophils in peripheral blood, spleen, bone marrow and heart 2
896 hours after AMI relative to the levels of intact controls (controls $n = 4$, AMI $n = 3$). **E**
897 Mean fluorescence intensity (MFI) of CD62L/L-selectin on neutrophils in peripheral
898 blood, spleen, bone marrow and heart 2 hours after AMI relative to the levels of
899 intact controls (controls $n = 4$, AMI $n = 3$). **F** Percentage of monocytes in peripheral
900 blood, spleen, bone marrow and heart 2 hours after AMI relative to the levels of
901 intact controls (controls $n = 4$, AMI $n = 3$). Pearson's correlation was used in **A** and
902 **B**, dotted lines represent 95% confidence interval and an unpaired t test was used
903 in **D**, **E** and **F** for statistical analysis. Error bars represent mean \pm SD ** $p < 0.01$,
904 *** $p < 0.001$.

905

906

907 **Figure 2. Plasma extracellular vesicles (EVs) are elevated in peripheral blood**
908 **following AMI. A** Plasma EV number (10^8 / mL) at time of presentation following
909 AMI and 6 months later in the same patients ($n = 15$). **B** Size and concentration
910 profile of plasma EVs at time of presentation following AMI and 6 months later in the
911 same patients ($n = 15$). Pearson's correlation of plasma EVs at time of presentation
912 versus: **C** extent of myocardial injury as determined by T2-weighted MRI, **D** LGE 6-
913 months post-AMI, **E** number of peripheral blood neutrophils following AMI (10^9 / L) (n
914 = 15). A paired t test was used for statistical analysis in **A** and **B**. Pearson's
915 correlation was used in **C**, **D** and **E**, dotted lines represent 95% confidence interval
916 for statistical analysis. ** $p < 0.01$

917

918 **Figure 3. Human umbilical cord vein endothelial cells (HUVEC) release more**
919 **extracellular vesicles (EVs) after inflammatory stimulation. A** HUVECs: express
920 more VCAM-1 following treatment with recombinant human tumour necrosis factor- α
921 (TNF- α) (10 ng / mL) ($n = 9$ per group); **B** release more EVs ($n = 8$ per group). **C**
922 Size and concentration profile of HUVEC derived EVs under basal conditions and
923 after inflammatory stimulation with recombinant human TNF- α ($n = 8$ per group). **D**
924 Transmission electron micrograph (TEM) of HUVEC-derived EVs (scale bar 100 nm)
925 and **E** cryo-TEM HUVEC-derived EVs (scale bar 50 nm). **F** Ponceau stain and
926 western blot of HUVEC derived EV from basal and after inflammatory stimulation
927 with TNF- α for eNOS, TSG101, CD9, ATP5A and Histone H3. HUVEC cell pellets
928 (CP), EV-depleted cell culture supernatants (EV-dep) and cell culture media that was
929 not exposed to cells (sham) were used as controls. EC-EV miRNA levels of **G** hsa-
930 miRNA-126-3p and **H** hsa-miRNA-126-5p under basal conditions and after
931 inflammatory stimulation with TNF- α ($n = 8$ per group). miRNA-126-mRNA targets in
932 human and mouse and their target pathways. **I** Euler plot of miRNA-126-mRNA
933 targets from TargetScanHuman, TargetScanMouse, miRWalk, miRDB for human
934 and the mouse. **J** Euler plot of Gene Ontology (GO) terms for miRNA-126-mRNA
935 targets for the human and mouse. Shape areas are approximately proportional to
936 number of genes. An unpaired t test was used in **A**, **B**, **C**, **G** and **H** for statistical
937 analysis. Error bars represent mean \pm SD ** $p < 0.01$, *** $p < 0.001$.

938

939 **Figure 4. RNA sequencing of peripheral blood neutrophils** following STEMI and
940 NSTEMI patients at the time of presentation versus a control sample obtained from
941 the same patients 1 month post-AMI ($n = 3$ per group). MA plots shows differential
942 transcriptome at the time of presentation versus a control sample obtained from the
943 same patients 1 month post-AMI in **A** NSTEMI and **B** STEMI patients. Significantly
944 altered genes are highlighted in red. **C** Euler plot showing similarity and differences
945 in the number of differentially expressed genes in NSTEMI and STEMI patients at
946 time of presentation versus 1 month follow-control samples or between all NSTEMI
947 and all STEMI patients ($n = 3$ per group). **D** Normalised enrichment scores are
948 shown for significantly enriched Hallmark gene sets from gene set enrichment
949 analysis (GSEA) of presentation versus 1 month follow-control samples from STEMI
950 patients ($n = 3$). **E** miRNA-126 antagomiR treatment of wild-type mice prior to
951 induction of AMI. **F** TTC staining of the myocardium 24 hours post-AMI in scramble
952 and antagomiR treated mice (scramble $n = 7$ and antagomiR $n = 5$ per group).
953 Significant differentially expressed (DE) genes in **A**, **B** and **C** were determined by
954 adjusted p -values below the 5% false discovery rate (FDR) threshold. Significantly
955 enriched gene sets in **D** were defined as having a Benjamini–Hochberg-adjusted
956 $p < 0.05$. **F** an unpaired t test was used for analysis. Error bars represent mean \pm SD
957 ** $p < 0.01$.

958

959 **Figure 5 Mouse sEND.1 endothelial cells release more extracellular vesicles**
960 **(EVs) after inflammatory stimulation. A** mouse sEND.1 endothelial cells express
961 more VCAM-1 following treatment with recombinant mouse tumour necrosis factor- α
962 (TNF- α) (10 ng / mL) ($n = 9$ per group); **B** release more EVs ($n = 11$ per group). **C**
963 Size and concentration profile of sEND.1 derived EVs under basal conditions ($n = 3$)
964 and after inflammatory stimulation with recombinant mouse TNF- α ($n = 4$). **D**
965 Transmission electron micrograph (TEM) of sEND.1-derived EVs (scale bar 1000
966 nm) and **E** cryo-TEM sEND.1-derived EVs (scale bar 1000 nm). **F** Ponceau stain and
967 western blot of sEND.1 derived EV from basal and after inflammatory stimulation
968 with TNF- α for ALIX, TSG101, CD9, eNOS, VCAM-1, ATP5A and Histone H3.
969 sEND1 cell pellets (CP), EV-depleted cell culture supernatants (EV-dep) and cell
970 culture media that was not exposed to cells (sham) were used as controls. EC-EV
971 miRNA levels of **G** hsa-miRNA-126-3p and **H** hsa-miRNA-126-5p under basal
972 conditions ($n = 8$) and after inflammatory stimulation with TNF- α ($n = 7$). An unpaired
973 t test was used in **A**, **B**, **C**, **G** and **H** for statistical analysis. Error bars represent
974 mean \pm SD ** $p < 0.01$, *** $p < 0.001$.

975

976

977 **Figure 6. Endothelial cell derived extracellular vesicles (EC-EV) localise to the**
978 **spleen in wild-type, mice and influence gene and protein expression. A** RT-
979 qPCR detection of EC-EV labelled with miRNA-39-3p in the spleen of mice following
980 intravenous injection of 1×10^9 EVs by tail vein at 2 ($n = 4$), 6 ($n = 4$) and 24 ($n = 6$)
981 hours post-injection. Sham ($n = 10$) represents a media only preparation control with
982 no EC-EVs. **B** Heat map showing gene expression in the spleen of mice following
983 intravenous injection of 1×10^9 EVs by tail vein at 2 ($n = 4$), 6 ($n = 4$) and 24 ($n = 6$)
984 hours post injection. Sham ($n = 10$) represents a media only preparation control with
985 no EC-EVs. Data shown as $\Delta\Delta\text{Ct}$ values normalised to row mean $\Delta\Delta\text{Ct}$ value for
986 each gene. **C** Heat map showing protein expression in the spleen of mice following
987 intravenous injection of 1×10^9 EVs by tail vein at 2 hours ($n = 4$) post-injection.
988 Sham ($n = 4$) represents a media only preparation control with no EC-EVs. Data
989 shown are chemokine array dot blot density values normalised to mean row value for
990 each protein. A one-way ANOVA with post-hoc Bonferroni correction was used in **A**,
991 **B** and an unpaired t test was used in **C**. Error bars represent mean \pm SD
992 ****** $p < 0.05$, ****** $p < 0.01$, ******* $p < 0.001$.

993

994 **Figure 7. Endothelial cell derived extracellular vesicles (EC-EV) (1×10^9 EVs /**
995 **mL) mobilise splenic-neutrophils in healthy mice. A** Percentage of neutrophils as
996 a proportion of the total leukocytes (live, CD45⁺, CD11b⁺, Ly6G⁺) in peripheral blood,
997 bone marrow and spleen ($n = 5$ per group). **B** Splenic-neutrophil mobilisation ratio
998 (peripheral blood neutrophils/ spleen neutrophils) shows net contributions of
999 neutrophil reserves to mobilised peripheral blood neutrophils following intravenous
1000 injections of EC-EV (1×10^9 EVs m mL) injections ($n = 5$ per group). **C** Mean
1001 fluorescent intensity (MFI) of CD62L/L-selectin on neutrophils in peripheral blood,
1002 spleen and bone marrow 2 hours after ($n = 5$ per group) intravenous injections of
1003 EC-EV (1×10^9 EVs / mL). An unpaired t test was used in **A**, **B** and **C**. Error bars
1004 represent mean \pm SD *** $p < 0.001$.

1005

1006

1007

1008 **Figure 8. Extracellular vesicle (EV) vascular cell adhesion molecule-1 (VCAM-1)**
1009 **is necessary for endothelial cell (EC)-EV splenic-neutrophil mobilisation. A**
1010 Transmission electron micrograph of a VCAM-1+ plasma EV bound to a magnetic
1011 bead of iron oxide (MPIO) conjugated with anti-human VCAM-1 antibodies, scale bar
1012 is 200nm. **B/C** Western blot of sEND.1 wild-type and CRISPR-cas9 base-edited
1013 VCAM-1 knock outs cell pellets under basal conditions (wild-type $n = 4$ and VCAM-1
1014 knock out $n = 4$ per group) and after inflammatory stimulation with recombinant
1015 mouse tumour necrosis (TNF- α). **D** The number of mouse sEND.1 endothelial cell
1016 derived extracellular vesicles (EC-EVs) from wild-type and CRISPR-cas9 base-
1017 edited VCAM-1 knock outs under basal conditions (wild-type $n = 12$ and VCAM-1
1018 knock out $n = 11$ per group) and after inflammatory stimulation with recombinant
1019 mouse tumour necrosis factor- α (TNF- α) ($n = 8$ per group). **E** Size and concentration
1020 profile of mouse sEND.1 EC-EVs from wild-type and CRISPR/Cas9 base-edited
1021 VCAM-1 knock outs under basal conditions (wild-type $n = 12$ and VCAM-1 knock out
1022 $n = 11$ per group) and after inflammatory stimulation with recombinant mouse tumour
1023 necrosis factor- α (TNF- α) ($n = 8$ per group). **F** Ponceau stain and western blot of
1024 wild-type and CRISPR-cas9 base-edited VCAM-1 knock out sEND.1 derived EVs
1025 from basal and after inflammatory stimulation with recombinant mouse TNF- α for
1026 TSG101, CD9 and VCAM-1. Inflammatory stimulated s.END1 cell pellets and EV-
1027 depleted cell culture supernatants were used as controls. **G** RT-qPCR detection of
1028 wild-type sEND.1 and CRISPR-cas9 base-edited VCAM-1 knock outs EC-EV
1029 labelled with miRNA-39-3p in the spleen of mice following intravenous injection of $1 \times$
1030 10^9 EVs by tail vein at 2 hours post-injection ($n = 5$ per group). **H** Heat map showing
1031 mRNA expression in the spleen of mice following intravenous injection of wild-type or
1032 CRISPR-cas9 base-edited VCAM-1 knock out EC-EVs 1×10^9 EVs by tail vein at 2

1033 hours post-injection. Sham represents a media only preparation control with no EC-
1034 EVs ($n = 5$ per group). Data shown as $\Delta\Delta\text{Ct}$ values normalised to row mean $\Delta\Delta\text{Ct}$
1035 value for each gene. **I/J** Percentage of neutrophils as a proportion of the total
1036 leukocytes (live, CD45^+ , CD11b^+ , Ly6G^+) in peripheral blood and spleen (sham and
1037 VCAM-1 knock out EC-EV $n = 4$ and wild-type EC-EV $n = 5$ per group). **I** Splenic-
1038 neutrophil mobilisation ratio (peripheral blood neutrophils/ spleen neutrophils) shows
1039 net contributions of splenic reserves to mobilised peripheral blood neutrophils
1040 following intravenous injections of wild-type or CRISPR-cas9 base-edited VCAM-1
1041 knock out EC-EVs 1×10^9 EVs by tail vein at 2 hours post injection. Sham represents
1042 a media only preparation control with no EC-EVs (sham and VCAM-1 knock out EC-
1043 EV $n = 3$ and wild-type EC-EV $n = 5$ per group). One-way (**H**, **I** and **J**) and two-way
1044 (**B**, **C**, **D** and **E**) ANOVA with post-hoc Bonferroni correction was used for statistical
1045 analysis. An unpaired t test was used in **F**. Error bars represent mean \pm SD
1046 * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, **** $p < 0.0001$.

1047

1048 **Supplementary Table 1** miRNA-126-mRNA targets in the human, mouse and the
1049 overlap between both species.

1050 **Supplementary Table 2** miRNA-126-mRNA target pathways using gene ontology
1051 (GO) in the human, mouse and the overlap between both species.

1052 **Supplementary Table 3** P-values are shown from a Fisher's exact test used to
1053 detect enrichment of curated miRNA-126-mRNA targets versus gene sets for
1054 neutrophil GO terms.

1055 **Supplementary Table 4** GO biological process and Reactome pathway analysis of
1056 differentially enriched genes in human neutrophils from STEMI patients at the time of
1057 injury.

1058 **Supplementary Table 5** GO (biological process, molecular function and cellular
1059 component) and Reactome pathway analysis in single cell RNA-sequencing of
1060 differentially enriched genes in neutrophil blood population 1 follow AMI.

1061 **Supplementary Table 6** GO (biological process, molecular function and cellular
1062 component) and Reactome pathway analysis in single cell RNA-sequencing of
1063 differentially enriched genes in neutrophil blood population 2 follow AMI.

1064 **Supplementary Table 7** GO (biological process, molecular function and cellular
1065 component) and Reactome pathway analysis in single cell RNA-sequencing of
1066 differentially enriched genes in neutrophil blood population 3 follow AMI.

1067 **Supplementary Table 8** P-values are shown from a Fisher's exact test used to
1068 detect enrichment of differentially enriched genes in human peripheral blood
1069 neutrophil versus single cell RNA-sequencing of blood neutrophils from the mouse
1070 following AMI.

1071

1072 **Supplementary Table 9** P-values and Jaccard index are shown from a Fisher's
1073 exact test used to detect enrichment of differentially enriched gene target pathways
1074 using GO (biological process, molecular function and cellular component) and
1075 Reactome pathway analysis from human peripheral blood neutrophil versus single
1076 cell RNA-sequencing of blood neutrophils from the mouse following AMI.

1077 **Supplementary Table 10** miRNA-126-mRNA targets from the human, mouse and
1078 the overlap (present in human and mouse) were compared with differentially
1079 expressed (DE) genes and the not-DE (NDE) genes in the neutrophil transcriptomes
1080 at time of presentation with AMI.

1081 miRNA-126-mRNA targets from the human, mouse and the overlap (present in
1082 human and mouse) were compared with differentially expressed (DE) genes and the
1083 not-DE (NDE) genes in single cell RNA-sequencing of differentially enriched genes
1084 in neutrophil blood and heart populations following AMI.

1085

1086 **Supplementary OxAMI.** Author acknowledgments for the Oxford Acute Myocardial
1087 Infarction Study.


1088

1089 **Supplementary Methods.** Details of experimental methods and reagents.

1090

1091 **Supplementary uncropped western blots.** Unedited images of western blot
1092 membranes

Figure 1




OxAMI Study



Plasma EV

Presentation 6 months

Figure 2












Figure 4








Group

- Sham
- 2 Hours
- 6 Hours
- 24 Hours

Group

- Sham
- EC-EV






Figure 8

